Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Dannon To Unveil Yogurt Made With Non-GMO Ingredients, New Transparent Labeling

XTALKS VITALS NEWS

Yogurt

Dannon says their brands – including Danimals, Oikos and Dannon – will all eventually move towards the use of non-GMO ingredients.

Tweetables from this article:

Tweet: Dannon will begin making a new line of yogurt products containing non-GMO ingredients http://ctt.ec/ef7sX+Dannon will begin making a new line of yogurt products containing non-GMO ingredients.

Tweet: Dannon: 80,000 acres of farmland to be converted to grow non-GMO crops http://ctt.ec/bU_Zd+Dannon: 80,000 acres of farmland to be converted to grow non-GMO crops.

Share this!

July 26, 2016 | by Sarah Massey, M.Sc.

In an effort to give consumers more choices, Dannon will begin making a new line of yogurt products containing non-GMO ingredients. In addition, the company will now begin to voluntarily label any products that contain GMOs, to make the difference between the products clearer.

Dannon says their brands – including Danimals, Oikos and Dannon – will all eventually move towards the use of non-GMO ingredients. Starting next year, the company plans to ensure that all milk used in their products will be produced by cows fed non-GMO feed.

The company estimates this will require around 80,000 acres of farmland to be converted to grow non-GMO crops, in order to feed the dairy cows from which the milk for the yogurt products will be collected. The New York-based company says this move is a first for a big, non-organic yogurt manufacturer.

“Shoppers are our main ingredient, and what is important to them drives what we do. For this reason, the range of products we make is evolving to provide even more choices,” said Mariano Lozano, CEO of Dannon. “Transparency is the key word for this shift. To show to our consumers that in order to make a real choice, we need clear labels, today we are making a bold change and candidly discussing how transparency from brands is essential for shoppers to make real choices.”



In order to reach these objectives, Dannon has partnered with a number of Non-Government Organizations (NGOs), including Green America and the Non-GMO Project. Dannon has also partnered with Just Label It! To help them add more information to their product labels. This transparency in labeling is just the first step in the company’s Dannon Pledge.

Along with increasing labeling transparency and improving sustainable dairy farming, Dannon has also vowed to create more choices for consumers, including eventually using fewer, and more natural ingredients in its Dannon, Danimals and Oikos. These three brands make up nearly 50 percent of the company’s total sales.

“Choosing to purchase foods with fewer or more natural ingredients, or with or without GMO ingredients, is an important individual decision, and we feel strongly that people have the right to know how companies are making food. This is just the first of many steps towards our continued transparency and one that we hope others will follow,” said Lozano. “And we're not just doing this alone. Dannon is proud to have the support of the Non-GMO Project, Green America and Just Label It.”


Keywords: Food, GMO, Labeling


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.